Apellis Pharmaceuticals (APLS) Announces Results of Phase 3 DERBY and OAKS Studies in Geographic Atrophy, Plans NDA

Wedbush Downgrades Apellis Pharmaceuticals (APLS) to Neutral

September 10, 2021 7:29 AM EDT

Wedbush analyst Laura Chico downgraded Apellis Pharmaceuticals (NASDAQ: APLS) from Outperform to Neutral with a price target of $39.00 (from $71.00).

The analyst commented, "Our prior upgrade was predicated on the pivotal DERVY/OAKS studies holding a high probability of success (>80%) for at least the monthly... More

Apellis Pharmaceuticals (APLS) PT Lowered to $65 at Oppenheimer

September 10, 2021 6:58 AM EDT

Oppenheimer analyst Justin Kim lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $65.00 (from $80.00) while maintaining an Outperform rating.

The analyst commented, "On 9/9, Apellis reported mixed top-line results from its Phase 3 DERBY and OAKS studies (n=1,258) of pegcetacoplan in geographic... More

Apellis Pharmaceuticals (APLS) PT Lowered to $70 at Needham & Company

September 10, 2021 6:54 AM EDT

Needham & Company analyst Joseph Stringer lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $70.00 (from $85.00) while maintaining a Buy rating.

The analyst commented, "APLS announced yesterday results from the Ph3 DERBY and OAKS trials evaluating pegcetacoplan in Geographic Atrophy (GA). The... More

Apellis Pharmaceuticals (APLS) PT Lowered to $69 at BMO Capital, Overall Data 'Should Still be Enough'

September 10, 2021 6:40 AM EDT

BMO Capital analyst Matthew Luchini lowered the price target on Apellis Pharmaceuticals (NASDAQ: APLS) to $69.00 (from $89.00) while maintaining an Outperform rating, saying the "totality of data plus the unmet need in GA provides reasonable basis for approval and recommend taking advantage of current... More

Apellis Pharmaceuticals (APLS) to Resume Trading at 4:35 p.m.

September 9, 2021 4:14 PM EDT

Apellis Pharmaceuticals (NASDAQ: APLS) to Resume Trading at 4:35 p.m.

... More

UPDATE: IVERIC bio (ISEE) Gains Following Results From Apellis Pharmaceuticals (APLS)

September 9, 2021 4:14 PM EDT

(Updated - September 9, 2021 4:22 PM EDT)

IVERIC bio (NASDAQ: ISEE) Strength Post-Market Said Tied to Results from Apellis Pharmaceuticals (NASDAQ: APLS)

Shares Up 17%

Update:

Shares Are Now Up 22%Catalyst Biosciences (NASDAQ: CBIO) Also Gained, up 15%... More